Trial reportTrials2026
The role of probiotics in the treatment of endometriosis (ProMetrioS): a randomized double-blinded placebo-controlled cross-over trial.
Trial report in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06929364 (The Role of Probiotics in the Treatment of Endometriosis), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role of Probiotics in the Treatment of Endometriosis (ProMetrioS): a Randomised Double-blinded Placebo-controlled Cross-over Trial
Who cites it
1 citing paper in PubMed.
- Orchestrating the gut microbiota-mitochondrial-immune axis in gynecological diseases: mechanisms and dual-targeting therapeutic strategies.Frontiers in reproductive health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProMetrioS is a randomized, blinded, placebo-controlled cross-over trial investigating the effect of a specific multispecies probiotic in patients with endometriosis. The aim of this clinical trial is to determine whether probiotic treatment can significantly modulate gut microbiome composition and functionality in endometriosis patients, particularly parameters associated with the estrobolome.
methodsThis is a double-blinded, randomized, cross-over, placebo-controlled trial. Participants are randomly allocated to receive either 3 g of a probiotic formulation daily or a placebo for 8 weeks in two study phases, separated by a 8-week washout period. The gut microbiome is analyzed at four timepoints: start of thestudy, after phase 1, after the washout phase, and at the end of the study (after phase 2) amplicon sequencing. Quality of life related to endometriosis is assessed using validated questionnaires in the same four timepoints. Our primary endpoint is the favorable modulation of the gut microbiome, particularly with respect to the estrobolome. Secondary endpoints include changes in quality of life, reported symptomatology, and psychophysical condition. DISCUSSION: The findings of this study will provide the first evidence for the use of a combination of probiotics in the treatment of endometriosis. The results are expected at the end of 2025.
trial registrationClinicalTrials.gov (NCT06929364).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.